These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16237740)

  • 1. Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues.
    Van Eijck CH
    Br J Surg; 2005 Nov; 92(11):1333-4. PubMed ID: 16237740
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of endocrine gastroenteropancreatic tumors with somatostatin analogues.
    Fehmann HC; Wulbrand U; Arnold R
    Recent Results Cancer Res; 2000; 153():15-22. PubMed ID: 10626286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours].
    Colao A; Pulcrano M; Dorato M; Müller F; Rossi FW; De Martino MC; Biondi B; Lombardi G
    Minerva Endocrinol; 2001 Dec; 26(4):231-8. PubMed ID: 11782708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
    Kwekkeboom DJ; Teunissen JJ; Kam BL; Valkema R; de Herder WW; Krenning EP
    Hematol Oncol Clin North Am; 2007 Jun; 21(3):561-73; x. PubMed ID: 17548040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives.
    Capurso G; Fazio N; Festa S; Panzuto F; De Braud F; Delle Fave G
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):110-24. PubMed ID: 19249226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis.
    Burgess JR; Greenaway TM; Parameswaran V; Shepherd JJ
    Cancer; 1999 Nov; 86(10):2154-9. PubMed ID: 10570446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
    Uomo G; Germano D; Rabitti PG
    Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors.
    Trautmann ME; Neuhaus C; Lenze H; Benning R; Benning M; Dennler HJ; Bruns C; Joseph K; Arnold R
    Horm Metab Res Suppl; 1993; 27():24-7. PubMed ID: 8392487
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.
    Angeletti S; Corleto VD; Schillaci O; Marignani M; Annibale B; Moretti A; Silecchia G; Scopinaro F; Basso N; Bordi C; Delle Fave G
    Gut; 1998 Jun; 42(6):792-4. PubMed ID: 9691916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Somatostatin receptors in meningioma: diagnostic and therapeutic value].
    Prat R; Banzo J; Díaz FJ
    Rev Neurol; 1997 Dec; 25(148):2002-5. PubMed ID: 9528047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors.
    Degen L; Beglinger C
    Digestion; 1999; 60 Suppl 2():9-14. PubMed ID: 10207226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
    Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
    Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
    Simonenko VB; Dulin PA; Makanin MA
    Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological treatment of gastroenteropancreatic apudomas with an analog of somatostatin, SMS 201-995 (octreotide)].
    Varas Lorenzo MJ
    Rev Esp Enferm Dig; 1991 Feb; 79(2):95-8. PubMed ID: 2059523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours.
    Shah T; Caplin M
    Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):617-36. PubMed ID: 16183531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of the expression of somatostatin receptors in digestive endocrine tumours.
    Capurso G; Panzuto F; Delle Fave G
    Dig Liver Dis; 2010 Mar; 42(3):173-4. PubMed ID: 20117969
    [No Abstract]   [Full Text] [Related]  

  • 17. [Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas].
    Hansen CP; Knigge U
    Ugeskr Laeger; 2008 Jun; 170(24):2145-8. PubMed ID: 18565299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Contribution of synthetic somatostatin analogues to the clinical features of gastroenteropancreatic endocrine tumors].
    Biliotti G
    G Chir; 2006 Apr; 27(4):129-31. PubMed ID: 16768865
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
    Arnold R; Neuhaus C; Trautmann ME
    Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
    [No Abstract]   [Full Text] [Related]  

  • 20. 111In-octreotide scintigraphy: a tool to select patients with endocrine pancreatic tumors for octreotide treatment?
    Keymeulen B; Bossuyt A; Peeters TL; Somers G
    Ann Nucl Med; 1995 Aug; 9(3):149-52. PubMed ID: 8534589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.